Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

3IMpassion-132 (ITT population), 2024 IMpassion-132 (PD-L1 positive population), 2024 TBCRC, 20241Alice, 20228KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019 KEYNOTE-119 (all population), 2019 KEYNOTE-119 (all population) DUPLICATE, 2019 KEYNOTE-119 (PD-L1 CPS of 1 or more) DUPLICATE, 2019 KEYNOTE-119 (PD-L1 CPS of 10 or more), 2019 KEYNOTE-119 (PD-L1 positive CPS = 10 or more), 2019 KEYNOTE-119 PD-L1 positive (CPS = 1 or more), 20191EMBRACA, 20181OlympiAD, 20172ASCENT (all population), 2021 ASCENT (patients without brain metastases), 2021olaparib vs. pembrolizumab alone 1.01 [0.74; 1.40]1.01 [0.74;1.40]olaparib vs. pembrolizumab alone 1.01 [0.74; 1.40]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]1.82 [1.28;2.57]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]0.90 [0.66;1.23]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]olaparib vs. talazoparib 1.06 [0.72; 1.57]1.06 [0.72;1.57]olaparib vs. talazoparib 1.06 [0.72; 1.57]pembrolizumab alone vs. olaparib 0.99 [0.72; 1.36]0.99 [0.72;1.36]pembrolizumab alone vs. olaparib 0.99 [0.72; 1.36]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.79 [1.51; 2.12]1.79 [1.51;2.12]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.79 [1.51; 2.12]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.89 [0.82; 0.96]0.89 [0.82;0.96]pembrolizumab alone vs. Standard of Care (SoC) pembrolizumab alone better 0.89 [0.82; 0.96]pembrolizumab alone vs. talazoparib 1.05 [0.82; 1.34]1.05 [0.82;1.34]pembrolizumab alone vs. talazoparib 1.05 [0.82; 1.34]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]0.55 [0.39;0.78]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.56 [0.47; 0.66]0.56 [0.47;0.66]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.56 [0.47; 0.66]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]0.50 [0.43;0.58]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]0.58 [0.44;0.77]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]1.11 [0.81;1.52]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.13 [1.04; 1.22]1.13 [1.04;1.22]Standard of Care (SoC) vs. pembrolizumab alone pembrolizumab alone better 1.13 [1.04; 1.22]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]2.02 [1.74;2.35]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]1.18 [0.93;1.49]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]talazoparib vs. olaparib 0.94 [0.64; 1.39]0.94 [0.64;1.39]talazoparib vs. olaparib 0.94 [0.64; 1.39]talazoparib vs. pembrolizumab alone 0.95 [0.75; 1.22]0.95 [0.75;1.22]talazoparib vs. pembrolizumab alone 0.95 [0.75; 1.22]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]1.71 [1.29;2.26]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]0.85 [0.67;1.07]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]Standard of Care (SoC)carboplatingemcitabinepegylated liposomal doxorubicin and cyclophosphamidepembrolizumab aloneatezolizumab based treatmenttalazoparibolaparibsacituzumab govitecandirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)carboplatingemcitabinepegylated liposomal doxorubicin and cyclophosphamidepembrolizumab aloneatezolizumab based treatmenttalazoparibolaparibsacituzumab govitecan
Standard of Care (SoC)---NANANA1.13
1.04; 1.22		NA1.18
0.93; 1.49		1.11
0.81; 1.52		2.02
1.74; 2.35
carboplatinNA---NANANANANANANA
gemcitabineNANA---NANANANANANA
pegylated liposomal doxorubicin and cyclophosphamideNANANA---NANANANANA
pembrolizumab alone0.89
0.82; 0.96		NANANA---NA1.05
0.82; 1.34		0.99
0.72; 1.36		1.79
1.51; 2.12
atezolizumab based treatmentNANANANANA---NANANA
talazoparib0.85
0.67; 1.07		NANANA0.95
0.75; 1.22		NA---0.94
0.64; 1.39		1.71
1.29; 2.26
olaparib0.90
0.66; 1.23		NANANA1.01
0.74; 1.40		NA1.06
0.72; 1.57		---1.82
1.28; 2.57
sacituzumab govitecan0.50
0.43; 0.58		NANANA0.56
0.47; 0.66		NA0.58
0.44; 0.77		0.55
0.39; 0.78		---

pathologies: 270,140,240 - treatments: 1232 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons